Development of a novel, cost-effective, platform-based cell-sorting solution superior to current best-in-class

开发一种新颖、经济高效、基于平台的细胞分选解决方案，优于当前同类最佳解决方案

• 批准号: 88249
• 金额: $ 12.54万
• 依托单位: CELL LANE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=88249
• 关键词: Development; novel; cost; effective; platform

Founded by Dr Chris Wood (Associate Professor of High-Frequency and Mesoscopic Electronics), Christoph Wälti (Professor of Bionanotechnology) and Jennifer Kirkham (Professor of Oral Biology), Cell Lane (CL) is a growing UK-based SME specialising in cell-separation technologies to support next generation, regenerative cell therapies. Current cell-separation technologies are either inefficient, costly or introduce impurities, thereby slowing the advancement of cell therapies to treat a range of injuries and disease including cancer, Parkinson's disease, diabetes and stroke. CL aims to provide a novel, cost-effective, platform-based, cell-sorting solution superior to current best-in-class technologies. CL proposes a year-5 post-project revenue of £4.6M--6.2M.

Cell Lane（CL）由Chris Wood博士（高频和介观电子学副教授）、Christoph Wälti（生物纳米技术教授）和Jennifer Kirkham（口腔生物学教授）创立，是一家不断发展的英国中小企业，专门从事细胞分离技术，以支持下一代再生细胞疗法。目前的细胞分离技术要么效率低下，成本高昂，要么引入杂质，从而减缓了细胞疗法治疗一系列伤害和疾病的进展，包括癌症，帕金森病，糖尿病和中风。CL旨在提供一种新颖的、具有成本效益的、基于平台的细胞分选解决方案，该解决方案上级于当前同类最佳技术。CL提出的5年项目后收入为460万英镑至620万英镑。